遠大醫藥(00512.HK)擬2500萬美元購買美國生物醫藥公司OncoSec 44.2%股權
格隆匯10月10日丨遠大醫藥(00512.HK)公佈，於2019年10月10日，本公司直接全資擁有附屬公司弘年與OncoSec訂立了遠大股份購買協議，據此弘年有條件同意以代價2500萬美元購買1000萬股OncoSec股份，代表經遠大股份購買事項及Sirtex股份購買事項擴大後OncoSec股本的約44.2%。
按本公司所得悉，於2019年10月10日，Sirtex亦與OncoSec訂立了Sirtex股份購買協議，以每股購買價2.5美元購買200萬股OncoSec股份。Sirtex購買的2,000,000股OncoSec股份代表經遠大股份購買事項及Sirtex股份購買事項擴大後的OncoSec股本的約8.8%。遠大股份購買事項及Sirtex股份購買事項的完成條件是互為條件的，並預期會同時發生。
據悉，OncoSec為一間於美國內華達州成立的公司並於Nasdaq上市，是一間已進行臨牀階段的生物技術公司，主要為開發細胞激素為基礎的腫瘤內免疫療法，使用新技術以刺激人體的免疫系統以靶向攻擊癌症。OncoSec於截至2017年及2018年7月31日止年度分別虧損2140萬美元及3910萬美元。
按董事所知，OncoSec為一間已進入臨牀階段的創新生物技術公司，主要為開發細胞激素為基礎的腫瘤內免疫療法，使用其專有的電穿孔傳遞技術以刺激人體的免疫系統，並逆轉腫瘤治療中的免疫抑制微環境，活化免疫細胞以達到靶向並攻擊腫瘤細胞的目的。
OncoSec的首創免疫療法產品–TAVO(Tavokinogene Telseplasmid)使以DNA為基礎的白介素-12(IL-12)能夠在腫瘤及其微環境中持續表達IL-12，以引發身體的免疫反應。IL-12是體內自有的促炎細胞因子，可以提高腫瘤局部的免疫原性並增加腫瘤浸潤淋巴細胞(TIL)，促進T細胞向腫瘤浸潤。
董事相信遠大股份購買協議連同授權協議下的交易可以向本公司提供潛在全球首創的癌症基因治療產品的系列，例如TAVO、VLA以及OncoSec研發中的其他產品。本公司於中國進行創新醫學產品的研發、學術推廣及產品上市有充足的經驗，並可運用其成熟的銷售網絡。本公司可預見引入OncoSec的產品到中國及其他亞洲國家有重大潛力，同時有助於進一步豐富本公司創新產品的儲備，加快本公司向國際化及研發創新轉型的步伐。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
